PALISADE BIO, INC.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

PALI$1.19+5.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

ance Sheets (Unaudited)

(in thousands, except share and per share amounts)

	March 31,	December 31,
	2026	2025
ASSETS
Current assets:
Cash and cash equivalents	$132,628	$133,385
Prepaid expenses and other current assets	615	836
Total current assets	133,243	134,221
Restricted cash	55	55
Other noncurrent assets	17	68
Total assets	$133,315	$134,344
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$2,696	$767
Accrued liabilities	2,802	2,187
Accrued compensation and benefits	122	1,298
Share liability	—	313
Insurance financing debt	—	71
Total current liabilities	5,620	4,636
Derivative liability	62	62
Contingent consideration obligation	271	266
Total liabilities	5,953	4,964
Commitments and contingencies (Note 9)
Stockholders' equity:
Series A Convertible Preferred Stock, $0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at March 31, 2026 and December 31, 2025	2	2
Common stock, $0.01 par value; 300,000,000 shares authorized;167,421,702 and 159,444,017 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	1,674	1,594
Additional paid-in capital	288,011	280,509
Accumulated deficit	(162,325)	(152,725)
Total stockholders' equity	127,362	129,380
Total liabilities and stockholders' equity	$133,315	$134,344

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.